Combination chelation therapy.
Yesim AydinokPublished in: Annals of the New York Academy of Sciences (2023)
Combination chelation therapies are considered in transfusion-dependent thalassemia patients for whom monotherapy regimens have failed to achieve iron balance or intensification of iron chelation therapy is required for the rapid reduction of excess iron to avoid permanent organ damage. Combination chelation may provide a more flexible approach for individualizing chelation therapy, thereby improving tolerability, adherence, and quality of life. In principle, iron chelators can be combined with an infinite number of dosing regimens; these involve simultaneous or sequential exposure to the chelators on the same day or alternating the drugs on different days. Clinical studies have established the safety and efficacy of chelation combinations. However, real-life data with combination therapies indicate the significance of compliance for a meaningful reduction in iron overload compared to monotherapies.
Keyphrases
- iron deficiency
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- open label
- oxidative stress
- ejection fraction
- randomized controlled trial
- clinical trial
- stem cells
- peritoneal dialysis
- type diabetes
- metabolic syndrome
- electronic health record
- big data
- patient reported outcomes
- sickle cell disease
- cell therapy
- machine learning
- artificial intelligence
- glycemic control
- double blind
- patient reported